Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

202015,297 citationsJournal Articlegreen Open Access

Authors

Fernando P. Polack · SUNY Upstate Medical University

Stephen J. Thomas · Johns Hopkins University

Nicholas Kitchin · Institut de Recherche Vaccinale

Judith Absalon · Johns Hopkins University

Alejandra Gurtman · Institut de Recherche Vaccinale

Stephen Lockhart · Institut de Recherche Vaccinale

John L. Perez

Abstract

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Viral gastroenteritis research and epidemiology Viral Infections and Immunology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 27, pp. 2603-2615

DOI: 10.1056/nejmoa2034577

Field-Weighted Citation Impact: 311.37